Key result
Dietary CL316,243 treatment for 4 weeks did not reverse atherosclerotic plaque burden in LDLR-deficient mice, despite reducing adiposity and plasma triglyceride levels.
Why the study?
It was unclear whether pharmacological activation of brown adipose tissue could be exploited therapeutically to reduce plaque burden in established atherosclerotic disease.
Does dietary CL316,243 treatment reduce atherosclerotic plaque burden in LDLR-deficient mice?
Does dietary CL316,243 treatment reduce atherosclerotic plaque burden in LDLR-deficient mice?
Pharmacological activation of thermogenic adipocytes improves metabolic profiles but does not reverse established atherosclerotic plaques in a preclinical model.
CL316,243 does not regress plaques in LDLR-/- mice; leaves open β3-agonist effects on human atherosclerosis.
Thermogenic adipocytes burn nutrients in order to produce heat. Upon activation, brown adipose tissue (BAT) clears vast amounts of lipids and glucose from the circulation and thus substantially lowers plasma lipid levels. As a consequence, BAT activation protects from the development of atherosclerosis. However, it is unclear if pharmacologic activation of BAT can be exploited therapeutically to reduce plaque burden in established atherosclerotic disease. Here we study the impact of thermogenic adipose tissues on plaque regression in a mouse model of atherosclerosis. Thermogenic adipocytes in atherosclerotic low-density lipoprotein (LDL) receptor (LDLR)-deficient mice were pharmacologically activated by dietary CL316,243 (CL) treatment for 4 weeks and the outcomes on metabolically active tissues, plasma lipids and atherosclerosis were analyzed. While the chronic activation of thermogenic adipocytes reduced adiposity, increased browning of white adipose tissue (WAT), altered liver gene expression, and reduced plasma triglyceride levels, atherosclerotic plaque burden remained unchanged. Our findings suggest that despite improving adiposity and plasma triglycerides, pharmacologic activation of thermogenic adipocytes is not able to reverse atherosclerosis in LDLR-deficient mice.
No takes yet. Share an insight, caveat, or question.
Worthmann et al. (2019) studied Atherosclerosis. Dietary CL316,243 (CL) was evaluated on Atherosclerotic plaque burden. Dietary CL316,243 treatment for 4 weeks did not reverse atherosclerotic plaque burden in LDLR-deficient mice, despite reducing adiposity and plasma triglyceride levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: